Who to Boost When: The Effect of Age and Dosing Interval on Delta and Omicron COVID-19 Incidence in the Open-label Phase of the COVE Trial.

Who to Boost When: The Effect of Age and Dosing Interval on Delta and Omicron COVID-19 Incidence in the Open-label Phase of the COVE Trial.

Publication date: Dec 01, 2024

To help inform COVID-19 vaccination recommendations, we evaluated the impact of age and dosing interval on clinical benefit of a third dose of mRNA-1273. Approximately 17 000 participants from the phase 3 Coronavirus Efficacy trial who previously received 2 doses of 100 ug mRNA-1273 were evaluated for COVID-19 between September 2021 and April 2022 during uptake of a third booster dose of 50 ug of mRNA-1273. Cox models assessed booster relative efficacy of a third dose. Initial booster relative efficacy against Delta COVID-19 was 83% (95% confidence interval, 60-93) 14 days postdose and 83% (67-91) 60 days later. Initial booster efficacy against Omicron COVID-19 was 56% (44-65) at 14 days postdose and 4% (-27 to 28) 120 days later. For those aged ≥65 years, initial booster efficacy against Omicron COVID-19 was 86% (69-93) compared with 50% (36-61) for those

Open Access PDF

Concepts Keywords
100g booster dose
April COVID-19 vaccine
Coronavirus mRNA-1273
Models SARS-CoV2

Semantics

Type Source Name
disease MESH COVID-19
disease MESH Infectious Diseases
drug DRUGBANK Etodolac
disease MESH Allergy
drug DRUGBANK Coenzyme M

Original Article

(Visited 1 times, 1 visits today)